Modality
Degrader
MOA
CD3xCD20
Target
IL-13
Pathway
Angiogenesis
NMOSDEndometrial Ca
Development Pipeline
Preclinical
~Feb 2021
→ ~May 2022
Phase 1
~Aug 2022
→ ~Nov 2023
Phase 2
Feb 2024
→ Dec 2027
Phase 2Current
NCT03436680
2,706 pts·NMOSD
2024-02→2027-12·Active
2,706 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-041.7y awayPh3 Readout· NMOSD
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2/3
Active
Catalysts
Ph3 Readout
2027-12-04 · 1.7y away
NMOSD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03436680 | Phase 2/3 | NMOSD | Active | 2706 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| MRN-7601 | Moderna | Phase 2 | IL-13 |